2nd Annual Virtual Tumor Board®: Integrating Emerging Testing Methodologies into Optimal Treatment Planning in GI Cancers

Register Now

November 15, 2022  4:30 PM - 6:00 PM ET

Overview

Management of gastrointestinal (GI) cancers is rapidly evolving as novel and emerging biomarkers and molecular testing strategies are informing treatment for a more individualized and targeted approach. The clinical relevance of emerging biomarkers and appropriate testing strategies in GI malignancies should be carefully considered in the context of patient-specific characteristics.

This live Virtual Tumor Board^® webcast will update physicians on the application of testing and treatment methodologies across GI malignancies by providing an overview of clinically relevant emerging biomarkers and testing methods used to inform treatment approaches. Following a presentation of the current and emerging biomarkers involved in the testing for and treatment of GI cancers, expert faculty will discuss a series of cases that highlight best practices in biomarker testing to guide treatment for patients with GI malignancies.

Target Audience

This educational activity is directed toward medical oncologists, pathologists, NP/PAs, nurses, and others who treat GI malignancies.

Learning Objectives

Upon completion of this activity, participants will be able to:

• Evaluate relevant biomarkers and molecular testing strategies to guide decision-making in gastrointestinal cancers
• Summarize the relevance of liquid biopsy approaches across gastrointestinal cancers
• Assess efficacy and safety data regarding targeted treatment options in gastrointestinal cancers
• Explain appropriate testing strategies in specific patient case scenarios to optimize management of gastrointestinal malignancies

The staff of Physicians’ Education Resource^®, LLC, have no relevant financial relationships with ineligible companies. 

PER^® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.